Comparative Pharmacology
Head-to-head clinical analysis: ACTHAR GEL AUTOINJECTOR versus CORTROPHIN ZINC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTHAR GEL AUTOINJECTOR versus CORTROPHIN ZINC.
ACTHAR GEL (AUTOINJECTOR) vs CORTROPHIN-ZINC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTHAR Gel (repository corticotropin injection) acts primarily by stimulating the adrenal cortex to secrete corticosteroids (cortisol, corticosterone, and aldosterone), which exert anti-inflammatory, immunosuppressive, and antiproliferative effects. The exact mechanism in specific indications (e.g., infantile spasms) is not fully understood but may involve modulation of the hypothalamic-pituitary-adrenal axis and direct effects on the central nervous system.
Corticotropin (ACTH) stimulates the adrenal cortex to release glucocorticoids, mineralocorticoids, and androgens. In gel formulation, zinc complex prolongs absorption, providing sustained adrenocortical stimulation.
Initial: 40-80 units intramuscularly or subcutaneously every 24-48 hours; maintenance: 20-40 units intramuscularly or subcutaneously every 48 hours. Titrate based on response.
40-80 units subcutaneously or intramuscularly every 24-72 hours, titrated to individual patient response.
None Documented
None Documented
The terminal half-life of exogenously administered ACTH is approximately 15 minutes; however, the duration of adrenal cortisol stimulation persists for 6-12 hours after IM administration due to prolonged absorption from the gel formulation.
Terminal half-life: 16-24 hours; clinical context: prolonged due to zinc complex, allows once-daily dosing
ACTH (corticotropin) is metabolized by tissue peptidases; renal excretion accounts for <5% of unchanged drug. Biliary/fecal elimination is negligible.
Renal: ~90% as metabolites; biliary/fecal: ~10%
Category C
Category C
Corticotropin
Corticotropin